Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Journal Article
PMID (42010121)
Authors Saifudeen M, Zhu S, Liang S, Eason M, Goupil A, Mische DF, Loch CM, Ma H, Chan M, Gujral TS
Title Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing.
URL
Abstract Text Protein kinases are central to cell signaling and key drug targets in cancer. To inform potential repurposing of kinase inhibitors, we profiled 86 of the ~100 approved kinase inhibitors against 758 kinases, including 409 wild-type and 349 oncogenic variants using a biochemical kinase assay. Our results increase the number of druggable kinases from 89 to 235, revealing that 94% of mutations and 97% of fusions represented in our samples are inhibited by at least one existing drug. The dataset revealed mutation-specific selectivity, especially in tyrosine kinases FGFR and MET, highlighting gaps and repurposing opportunities. We experimentally validated several actionable findings, including tepotinib to target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway in pancreatic cancer and gilteritinib to overcome MET mutation-driven drug resistance and metastasis. To facilitate exploration of our data, we provide KIRHub, a web-based tool that allows identification of existing inhibitors of wild-type and mutated kinases to guide precision oncology.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
FGFR2 C491A missense unknown FGFR2 C491A lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). C491A has been identified in the scientific literature (PMID: 25349422, PMID: 42010121), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Nov 2026).
FGFR2 C491S missense unknown FGFR2 C491S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). C491A has been identified in the scientific literature (PMID: 41361008, PMID: 42010121, PMID: 37270847), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Nov 2026).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR3 V555M Advanced Solid Tumor resistant Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR3 V555M were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). 42010121
FGFR2 C491A FGFR2 V564L Advanced Solid Tumor resistant Futibatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). 42010121
FGFR2 C491S FGFR2 V564L Advanced Solid Tumor resistant Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 C491S and FGFR2 V564L were resistant to Retevmo (selpercatinib) in culture (PMID: 42010121). 42010121
FGFR1 V561M Advanced Solid Tumor resistant Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR1 V561M were resistant to Balversa (erdafitinib) in culture (PMID: 42010121). 42010121
FGFR2 C491A FGFR2 V564L Advanced Solid Tumor resistant Infigratinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). 42010121
FGFR3 V555M Advanced Solid Tumor resistant Futibatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR3 V555M were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). 42010121
FGFR3 V555M Advanced Solid Tumor resistant Infigratinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR3 V555M were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). 42010121
FGFR2 C491A FGFR2 V564L Advanced Solid Tumor resistant Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). 42010121
FGFR3 V555M Advanced Solid Tumor predicted - sensitive Pralsetinib Preclinical - Cell culture Actionable In a preclinical study, Gavreto (pralsetinib) inhibited viability in cells expressing FGFR3 V555M in culture (PMID: 42010121). 42010121
FGFR2 C491S FGFR2 V564L Advanced Solid Tumor resistant Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2 C491S and FGFR2 V564L were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). 42010121
FGFR1 V561M Advanced Solid Tumor resistant Futibatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR1 V561M were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). 42010121
FGFR1 V561M Advanced Solid Tumor predicted - resistant Infigratinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR1 V561M were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). 42010121
FGFR2 C491S FGFR2 V564L Advanced Solid Tumor sensitive Erdafitinib Case Reports/Case Series Actionable In a preclinical study, Balversa (erdafitinib) inhibited viability in cells expressing FGFR2 C491S and FGRF2 V564L in culture (PMID: 42010121). 42010121
FGFR1 V561M Advanced Solid Tumor predicted - sensitive Pralsetinib Preclinical - Cell culture Actionable In a preclinical study, Gavreto (pralsetinib) inhibited viability in cells expressing FGFR1 V561M in culture (PMID: 42010121). 42010121
FGFR3 V555M Advanced Solid Tumor sensitive Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, Balversa (erdafitinib) inhibited viability in cells expressing FGFR3 V555M in culture (PMID: 42010121). 42010121
FGFR2 C491A FGFR2 V564L Advanced Solid Tumor sensitive Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, Balversa (erdafitinib) decreased phosphorylation of Fgfr, Akt and S6rp, and inhibited viability in cells expressing FGFR2 C491A and FGFR2 V564L in culture (PMID: 42010121). 42010121
FGFR2 C491A FGFR2 V564L Advanced Solid Tumor predicted - sensitive Pralsetinib Preclinical - Cell culture Actionable In a preclinical study, Gavreto (pralsetinib) decreased phosphorylation of Fgfr, Akt and S6rp, and inhibited viability in cells expressing FGFR2 C491A and FGFR2 V564L in culture (PMID: 42010121). 42010121
FGFR1 V561M Advanced Solid Tumor resistant Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR1 V561M were resistant to Retevmo (selpercatinib) in culture (PMID: 42010121). 42010121